BE2017C067I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C067I2
BE2017C067I2 BE2017C067C BE2017C067C BE2017C067I2 BE 2017C067 I2 BE2017C067 I2 BE 2017C067I2 BE 2017C067 C BE2017C067 C BE 2017C067C BE 2017C067 C BE2017C067 C BE 2017C067C BE 2017C067 I2 BE2017C067 I2 BE 2017C067I2
Authority
BE
Belgium
Prior art keywords
warm
treatment
allergy
mastocytosis
angioedema
Prior art date
Application number
BE2017C067C
Other languages
English (en)
French (fr)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C067(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BE2017C067I2 publication Critical patent/BE2017C067I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BE2017C067C 2003-06-18 2017-12-19 BE2017C067I2 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47957503P 2003-06-18 2003-06-18
EP04740016A EP1638574B1 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives
PCT/EP2004/006562 WO2004112794A2 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives

Publications (1)

Publication Number Publication Date
BE2017C067I2 true BE2017C067I2 (da) 2023-08-09

Family

ID=33539193

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C067C BE2017C067I2 (da) 2003-06-18 2017-12-19

Country Status (24)

Country Link
US (2) US8575146B2 (da)
EP (1) EP1638574B1 (da)
JP (2) JP5057780B2 (da)
CN (2) CN100457111C (da)
AT (1) ATE464052T1 (da)
AU (1) AU2004248909B2 (da)
BE (1) BE2017C067I2 (da)
BR (1) BRPI0411563B8 (da)
CA (2) CA2785950A1 (da)
CY (2) CY1110179T1 (da)
DE (1) DE602004026578D1 (da)
DK (1) DK1638574T3 (da)
ES (1) ES2344700T3 (da)
FR (1) FR17C1063I2 (da)
HK (1) HK1095519A1 (da)
HU (1) HUS000503I2 (da)
LU (1) LUC00055I9 (da)
MX (1) MXPA05013722A (da)
NL (1) NL300917I2 (da)
PL (1) PL1638574T3 (da)
PT (1) PT1638574E (da)
SI (1) SI1638574T1 (da)
TW (1) TWI324604B (da)
WO (1) WO2004112794A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
CN101693031A (zh) 2003-11-18 2010-04-14 诺瓦提斯公司 Kit突变形式的抑制剂
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
EP1778224B1 (en) * 2004-07-19 2014-03-26 The Johns-Hopkins University Flt3 inhibitors for immune suppression
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US20080176879A1 (en) * 2005-05-02 2008-07-24 Leila Alland Pyrimidylaminobenzamide Derivatives For Sytemic Mastocytosis
DE602006013826D1 (de) * 2005-07-20 2010-06-02 Peter Valent Zusammensetzungen zur behandlung von systemischer mastocytose
CA2629478C (en) * 2005-11-14 2013-10-15 Universitat Zurich Staurosporine derivatives for use in alveolar rhabdomyosarcoma
WO2009092442A1 (en) * 2008-01-23 2009-07-30 Universidad De Barcelona Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
EP2662078A1 (en) 2010-11-10 2013-11-13 National Jewish Health Methods to Treat Allergic Conditions
KR20210118812A (ko) 2018-11-01 2021-10-01 사이로스 파마수티컬스, 인크. 시클린-의존성 키나제 7 (cdk7)의 억제제
US11325978B2 (en) * 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639455A (en) * 1984-10-02 1987-01-27 Key Pharmaceuticals, Inc. Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
DE69229490T2 (de) 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Melatonin enthaltende Arzneimittel
AR004480A1 (es) 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
NZ333441A (en) * 1996-06-25 1999-05-28 Cephalon Inc Use of k-252a derivatives for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US6093740A (en) 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AU4423799A (en) * 1998-06-04 1999-12-20 Cornell Research Foundation Inc. Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
AU2002227371B2 (en) 2000-12-08 2007-05-10 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
CN1582150B (zh) * 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
EP1645286A1 (en) * 2003-04-18 2006-04-12 Kyowa Hakko Kogyo Co., Ltd. Drug for nerve regeneration
EP1637161A4 (en) 2003-04-22 2007-06-27 Astellas Pharma Inc MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
CN101693031A (zh) 2003-11-18 2010-04-14 诺瓦提斯公司 Kit突变形式的抑制剂

Also Published As

Publication number Publication date
TW200512213A (en) 2005-04-01
LUC00055I1 (da) 2017-12-14
HK1095519A1 (en) 2007-05-11
EP1638574A2 (en) 2006-03-29
CA2527703A1 (en) 2004-12-29
PT1638574E (pt) 2010-07-14
LUC00055I9 (da) 2022-11-09
HUS000503I2 (hu) 2021-03-29
FR17C1063I1 (da) 2018-02-16
CY2017048I2 (el) 2018-09-05
US8575146B2 (en) 2013-11-05
NL300917I2 (nl) 2018-01-09
CN101164539A (zh) 2008-04-23
PL1638574T3 (pl) 2010-09-30
DE602004026578D1 (de) 2010-05-27
DK1638574T3 (da) 2010-08-02
HUS1700053I1 (hu) 2018-01-29
ES2344700T3 (es) 2010-09-03
NL300917I1 (nl) 2017-12-12
JP2012144572A (ja) 2012-08-02
WO2004112794A2 (en) 2004-12-29
FR17C1063I2 (fr) 2019-05-03
CY2017048I1 (el) 2018-09-05
WO2004112794A3 (en) 2005-06-16
EP1638574B1 (en) 2010-04-14
US20130289018A1 (en) 2013-10-31
TWI324604B (en) 2010-05-11
CY1110179T1 (el) 2015-01-14
ATE464052T1 (de) 2010-04-15
BRPI0411563A (pt) 2006-08-01
CN1805749A (zh) 2006-07-19
JP2006527727A (ja) 2006-12-07
JP5057780B2 (ja) 2012-10-24
AU2004248909A1 (en) 2004-12-29
LUC00055I2 (da) 2018-02-21
BRPI0411563B8 (pt) 2021-05-25
SI1638574T1 (sl) 2010-08-31
MXPA05013722A (es) 2006-03-08
CA2527703C (en) 2012-10-23
AU2004248909B2 (en) 2008-05-08
BRPI0411563B1 (pt) 2019-09-24
CA2785950A1 (en) 2004-12-29
US20070299049A1 (en) 2007-12-27
CN100457111C (zh) 2009-02-04

Similar Documents

Publication Publication Date Title
FR17C1063I1 (da)
DK1611088T3 (da) Hydroxymater som terapeutiske midler
WO2003066579A3 (en) Novel bicyclic hydroxamates as inhibitors of histone deacetylase
ATE520668T1 (de) Sigmarezeptor-inhibitoren
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA201390353A1 (ru) Производное пиразолохинолина
EA200971053A1 (ru) Способы лечения кожных язв
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
GB2427405A (en) Novel hydroxamates as therapeutic agents
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
NO20051936L (no) Anvendelse av 4-pyridylmetyl-ftalazinderivater for fremstilling av et medikament for behandling av myelodysplastiske syndromer.
TH401002069A (th) การใช้แบบใหม่ของอนุพันธ์สเทาโรสพอรีน